Type II fatty acid synthesis is essential only for malaria parasite late liver stage development.

Vaughan AM, O'Neill MT, Tarun AS, Camargo N, Phuong TM, Aly AS, Cowman AF, Kappe SH. · 2009

Read Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. by Vaughan AM, O'Neill MT, Tarun AS, Camargo N, Phuong TM, Aly AS, Cowman AF, Kappe SH. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2688669.txt.

Introduction

Vaughan and colleagues found in 2009 that malaria parasites need their own fat-making machinery at exactly one step of their life cycle: the jump from liver to blood. The parasite carries a bacterial-style fat synthesis pathway in a small internal organ, long assumed vital in the blood stage that causes disease. The team deleted its key enzymes in a rodent malaria species.

Blood growth, mosquito stages, and the first invasion of the liver all proceeded normally without the pathway, a genuine surprise. Two separate enzyme knockouts agreed. Liver stages grew, but then failed at the last step: they could not form the invasive packets that burst out to seed the blood. Deleting the same enzyme in the human parasite likewise left blood growth untouched. A drug target once aimed at blood malaria, the authors conclude, belongs instead to the liver-to-blood handoff, useful for prevention rather than cure.

Catalog record

CREATORVaughan AM, O'Neill MT, Tarun AS, Camargo N, Phuong TM, Aly AS, Cowman AF, Kappe SH.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE68 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2688669

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Type II fatty acid synthesis is essential only for malaria parasite late liver stage development By Ashley M Vaughan, Matthew T O'Neill, Alice S Tarun, Nelly Camargo, Thuan M Phuong, Ahmed S I Aly, Alan F Cowman, Stefan H I Kappe Published in: Cellular Microbiology DOI: 10.1111/j.1462-5822.2008.01270.x ABSTRACT Abstract Intracellular malaria parasites require lipids for growth and replication. They possess a prokaryotic type II fatty acid synthesis (FAS II) pathway that localizes to the apicoplast plastid organelle and is assumed to be necessary for pathogenic blood stage replication. However, the importance of FAS II throughout the complex parasite life cycle remains unknown. We show in a rodent malaria model that FAS II enzymes localize to the sporozoite and liver stage apicoplast. Targeted deletion of FabB/F, a critical enzyme in fatty acid synthesis, did not affect parasite blood stage replication, mosquito stage development and initial infection in the liver. This was confirmed by knockout of FabZ, another critical FAS II enzyme. However, FAS II-deficient Plasmodium yoelii liver stages failed to form exo-erythrocytic merozoites, the invasive stage that first initiates blood stage infection. Furthermore, deletion of FabI in the human malaria parasite Plasmodium falciparum did not show a reduction in asexual blood stage replication in vitro. Malaria parasites therefore depend on the intrinsic FAS II pathway only at one specific life cycle transition point, from liver to blood. INTRODUCTION Malaria parasites are protists belonging to the genus Plasmodium. They are obligate intracellular parasites that have two distinct replicating life cycle forms in the mammalian host. A massive one-time replication occurs in the liver after inoculation of sporozoite stages by the bite of an infected mosquito and results in the production and release of tens of thousands infectious exo-erythrocytic merozoites (Prudencio et al., 2006). These merozoites infect red blood cells and initiate the cyclic replication that occurs within the blood stream. Blood stage infection leads to malaria disease with Plasmodium falciparum alone afflicting more than 500 million people annually (Snow et al., 2005). Plasmodium replication in red blood cells produces between 8 and 36 merozoites with each invasive cycle (Cowman and Crabb, 2006) whereas one-time replication in the infected hepatocyte produces up to 40 000 merozoites (Shortt et al., 1951) – an ∼2000-fold difference. It is currently not well understood to what extent malaria parasites rely on parasitic scavenging of nutrients versus intrinsic synthesis for growth and replication. Lipids are not only essential but are one of the most abundant components of all organisms and the malaria parasite needs a plentiful supply of lipids – specifically fatty acids for the membrane biogenesis necessary for invasive stage formation. Plasmodium parasites were initially assumed to lack the ability to synthesize their own fatty acids and thus rely on their hosts for lipid scavenging (Vial and Ancelin, 1992). However, this model came into question with the discovery of the apicoplast, a relict plastid organelle of Plasmodium (Kohler et al., 1997). Plant and algal plastids harbour several key biosynthetic pathways and the sequencing of the P. falciparum genome (Gardner et al., 2002) coupled with a detailed analysis of the proteins of known function that were targeted to the apicoplast (Foth et al., 2003) allowed the construction of an apicoplast-specific metabolic map (Ralph et al., 2004). The apicoplast is of cyanobacterial origin and one such apicoplast-targeted pathway is bacterial-like type II fatty acid synthesis (FAS II) (Waller et al., 1998), a de novo pathway by which Plasmodium can synthesize fatty acids from derivatives of acetate and malonate. The fatty acid chain extension step of FAS II is catalysed by four key enzymes – FabB/F, FabG, FabI and FabZ and the substrate/product of each reaction is covalently bound to the acyl carrier protein (ACP) cofactor (Fig. 1A). Conversely, the mammalian FAS I pathway utilizes a single enzyme complex and is not present in Plasmodium based on genome sequence analysis (Bahl et al., 2003). This is not the case for all apicomplexan parasites – the genome of Toxoplasma gondii encodes both FAS I and FAS II enzymes, Cryptosporidium parvum has FAS I enzyme whereas Theileria annulata does not harbour either FAS I or FAS II pathways (Mazumdar and Striepen, 2007). Deletion of ACP from T. gondii has demonstrated that apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in this parasite (Mazumdar et al., 2006). [Figure: Transcript abundance of genes involved in the extension step of type II fatty acid synthesis (FAS II) in Plasmodium yoelii. (A) FAS II takes place by the condensation of malonyl-ACP with acyl-ACP to form β-ketoacyl-ACP and CO2. This reaction is catalysed by 3-oxoacyl-ACP synthase I/II (FabB/F, P. yoelii PlasmoDB identifier PY04452). β-Ketoacyl-ACP is reduced by β-ketoacyl-ACP reductase (FabG, PY02416) to form β-hydroxyacyl-ACP, dehydrated by β-hydroxyacyl-ACP dehydratase (FabZ, PY01586) to form trans-2-enoyl-ACP and finally reduced by enoyl-acyl carrier reductase (FabI, PY3846) to acyl-ACP. Successive cycles utilizing these four enzymes add two carbon units per cycle. To quantitatively determine the transcript levels of genes encoding the enzymes involved in FAS II, RNA was extracted from different stages of the P. yoelii life cycle, reverse transcribed and used for quantitative PCR. Expression levels were measured in salivary gland sporozoites (SG SPZ), mixed blood stages (BS), blood stage schizonts (SCH), and in liver stages 12, 24, 40 and 50 h after salivary gland sporozoite infection (LS-12, LS-24, LS-40 and LS-50 respectively). The expression profile for (B) FabB/F, (C) FabI, (D) FabZ and (E) FabG are shown. Note that for all four genes, expression is highly upregulated in liver stages.] The four Plasmodium FAS II enzymes are promising drug targets because they are of bacterial origin. The P. falciparum enzymes have been expressed in vitro and used to reconstitute the elongation module of FAS II (Sharma et al., 2007). The in vitro system mimicked the in vivo machinery and known inhibitors of the enzymes of the elongation module caused the expected accumulation of intermediates. Thus, Plasmodium possesses a functional FAS II pathway. An early study identified a Plasmodium FabI and showed that the FabI inhibitor triclosan kills blood stage parasites (Surolia and Surolia, 2001) and subsequently a significant effort has been undertaken to develop blood stage FAS II inhibitors to treat malaria (Gornicki, 2003; Sato and Wilson, 2005; Wiesner and Seeber, 2005). Although the data suggested that FAS II is necessary for intra-erythrocytic replication, the expression of FAS II enzymes has not been studied throughout the complex infection cycle of the parasite and their importance in parasite progression throughout the life cycle remains unknown. We recently carried out a liver stage transcriptome and proteome analysis in the model rodent malaria parasite Plasmodium yoelii and observed that (i) the transcription of FAS II genes was increased in liver stages when compared with blood stages; (ii) FAS II enzymes were present in the liver stage proteome; and (iii) hexachlorophene, an inhibitor of FabG, was able to inhibit liver stage development in vitro (Tarun et al., 2008). These results suggested that FAS II might be important for parasite liver infection. Here, we show that expression of FAS II only occurs during the pre-erythrocytic phases of parasite infection and this allowed unprecedented imaging of the sporozoite and liver stage apicoplast. Strikingly, gene knockouts of FabB/F and FabZ, two of the

Read the complete text